HLS Therapeutics (TSE:HLS) Price Target Raised to C$4.00

HLS Therapeutics (TSE:HLS) had its price target increased by Stifel Nicolaus from C$3.50 to C$4.00 in a research note released on Wednesday,BayStreet.CA reports. They currently have a hold rating on the stock.

HLS Therapeutics Trading Up 3.1 %

Shares of TSE:HLS opened at C$4.66 on Wednesday. HLS Therapeutics has a 52 week low of C$3.00 and a 52 week high of C$5.48. The company’s 50 day moving average is C$4.19 and its two-hundred day moving average is C$3.81. The company has a market cap of C$103.67 million, a PE ratio of -4.67 and a beta of 1.07. The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.